Jian Wang1, Chenting Zhang2, Zili Zhang2, Zeguang Zheng2, Dejun Sun3, Quan Yang2, Cyrus Hadadi4, Defu Li2, Xiaoming Xu2, Mingmei Xiong2, Qipeng Zhou2, Meihua Guo2, Yingfeng Wang2, Chun Tang2, Guihua Xu3, Kai Yang2, Nanshan Zhong2, Wenju Lu2. 1. State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China; Department of Respiration, Inner Mongolia Autonomous Region People's Hospital, Hohhot 010017, Inner Mongolia, China; Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA. 2. State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. 3. Department of Respiration, Inner Mongolia Autonomous Region People's Hospital, Hohhot 010017, Inner Mongolia, China. 4. Geisinger Medical Center, 100 North Academy Avenue, Danville, PA 17822, USA.
Abstract
BACKGROUNDS: Bone morphogenetic protein receptor type 2 (BMPR2) signaling is anti-inflammatory. Decreased BMPR2 expression was seen in lung tissue from chronic obstructive pulmonary disease (COPD) patients. METHODS: The selected single nucleotide polymorphisms (SNPs) in BMPR2 were genotyped with polymerase chain reaction (PCR) ligase detection reaction. The effects of SNPs on gene expression were analyzed with luciferase assays. The mRNA and protein expression levels of BMPR2 in peripheral blood mononuclear cells (PBMCs) from COPD patients were determined by quantitative PCR and western blotting, respectively. FINDINGS: Two SNPs, rs6435156C > T and rs1048829G > T in the 3'-untranslated region (3'UTR) of BMPR2 were selected and genotyped in COPD case and healthy control subjects from southern Chinese population. Both of them were found associated with significantly increased COPD risk (adjusted odds ratio [OR] = 1.58 with 95% confidence interval [CI] = 1.14-2.15, P = 0.0056 for rs6435156C > T; adjusted OR = 1.47 and 95% CI = 1.10-1.97, P = 0.0092 for rs1048829G > T). Older age, cigarette smoking, family history of cancer and COPD were all factors that interacted with rs6435156C > T and rs1048829G > T causing increased COPD risk. Cigarette smokers with rs6435156 (CT + TT) or rs1048829 (GT + TT) were more susceptible to COPD than that with the rs6435156CC or rs1048829GG genotypes. In A549 human alveolar epithelial cells, luciferase reporter assays revealed that introduction of 3'UTR of BMPR2 plasmids carrying rs6435156T allele but not rs1048829T led to lower luciferase activity than the wild-type C or G alleles. Comparing to rs6435156CC, treatment with hsa-miR-20a mimics deceased whereas hsa-miR-20a inhibitor restored the luciferase reporter activity in cells transfected with constructs carrying rs6435156TT. BMPR2 mRNA and protein expressions were significantly lower in PBMCs from COPD smokers than that in non-smokers. COPD patients carrying rs6435156T allele had less BMPR2 expression in PBMCs. INTERPRETATION: This study demonstrated that both rs6435156C > T and rs1048829G > T variants in BMPR2 contributed to increased susceptibility to COPD. The T variants of rs6435156 increased COPD risk likely by binding with hsa-miR-20a, thus leading to downregulated BMPR2 expression in lung epithelial and immune cells.
BACKGROUNDS: Bone morphogenetic protein receptor type 2 (BMPR2) signaling is anti-inflammatory. Decreased BMPR2 expression was seen in lung tissue from chronic obstructive pulmonary disease (COPD) patients. METHODS: The selected single nucleotide polymorphisms (SNPs) in BMPR2 were genotyped with polymerase chain reaction (PCR) ligase detection reaction. The effects of SNPs on gene expression were analyzed with luciferase assays. The mRNA and protein expression levels of BMPR2 in peripheral blood mononuclear cells (PBMCs) from COPDpatients were determined by quantitative PCR and western blotting, respectively. FINDINGS: Two SNPs, rs6435156C > T and rs1048829G > T in the 3'-untranslated region (3'UTR) of BMPR2 were selected and genotyped in COPD case and healthy control subjects from southern Chinese population. Both of them were found associated with significantly increased COPD risk (adjusted odds ratio [OR] = 1.58 with 95% confidence interval [CI] = 1.14-2.15, P = 0.0056 for rs6435156C > T; adjusted OR = 1.47 and 95% CI = 1.10-1.97, P = 0.0092 for rs1048829G > T). Older age, cigarette smoking, family history of cancer and COPD were all factors that interacted with rs6435156C > T and rs1048829G > T causing increased COPD risk. Cigarette smokers with rs6435156 (CT + TT) or rs1048829 (GT + TT) were more susceptible to COPD than that with the rs6435156CC or rs1048829GG genotypes. In A549human alveolar epithelial cells, luciferase reporter assays revealed that introduction of 3'UTR of BMPR2 plasmids carrying rs6435156T allele but not rs1048829T led to lower luciferase activity than the wild-type C or G alleles. Comparing to rs6435156CC, treatment with hsa-miR-20a mimics deceased whereas hsa-miR-20a inhibitor restored the luciferase reporter activity in cells transfected with constructs carrying rs6435156TT. BMPR2 mRNA and protein expressions were significantly lower in PBMCs from COPD smokers than that in non-smokers. COPDpatients carrying rs6435156T allele had less BMPR2 expression in PBMCs. INTERPRETATION: This study demonstrated that both rs6435156C > T and rs1048829G > T variants in BMPR2 contributed to increased susceptibility to COPD. The T variants of rs6435156 increased COPD risk likely by binding with hsa-miR-20a, thus leading to downregulated BMPR2 expression in lung epithelial and immune cells.
Authors: Krystyna Teichert-Kuliszewska; Michael J B Kutryk; Michael A Kuliszewski; Golnaz Karoubi; David W Courtman; Liana Zucco; John Granton; Duncan J Stewart Journal: Circ Res Date: 2005-12-15 Impact factor: 17.367
Authors: Tsun-Po Yang; Claude Beazley; Stephen B Montgomery; Antigone S Dimas; Maria Gutierrez-Arcelus; Barbara E Stranger; Panos Deloukas; Emmanouil T Dermitzakis Journal: Bioinformatics Date: 2010-08-10 Impact factor: 6.937
Authors: Benjamin Sztrymf; Florence Coulet; Barbara Girerd; Azzedine Yaici; Xavier Jais; Olivier Sitbon; David Montani; Rogério Souza; Gerald Simonneau; Florent Soubrier; Marc Humbert Journal: Am J Respir Crit Care Med Date: 2008-03-20 Impact factor: 21.405
Authors: Matthias Brock; Michelle Trenkmann; Renate E Gay; Beat A Michel; Steffen Gay; Manuel Fischler; Silvia Ulrich; Rudolf Speich; Lars C Huber Journal: Circ Res Date: 2009-04-23 Impact factor: 17.367
Authors: Erika B Rosenzweig; Jane H Morse; James A Knowles; Kiran K Chada; Amar M Khan; Kari E Roberts; Jude J McElroy; Nicole K Juskiw; Nicole C Mallory; Stuart Rich; Beverly Diamond; Robyn J Barst Journal: J Heart Lung Transplant Date: 2008-04-09 Impact factor: 10.247
Authors: Klaus F Rabe; Suzanne Hurd; Antonio Anzueto; Peter J Barnes; Sonia A Buist; Peter Calverley; Yoshinosuke Fukuchi; Christine Jenkins; Roberto Rodriguez-Roisin; Chris van Weel; Jan Zielinski Journal: Am J Respir Crit Care Med Date: 2007-05-16 Impact factor: 21.405
Authors: K Zhang; B H Cheng; L L Yang; Z P Wang; H L Zhang; S S Xu; S Z Wang; Y X Wang; H Zhang; H Li Journal: J Anim Sci Date: 2017-11 Impact factor: 3.159
Authors: John W Sleasman; Maureen M Goodenow; Li Yin; Ashok R Dinasarapu; Samiksha A Borkar; Kai-Fen Chang; Kristina De Paris; Julie J Kim-Chang Journal: Retrovirology Date: 2022-05-31 Impact factor: 3.768